Clinical outcomes patients with high tumor mutational burden, high microsatellite stability, and mismatch repair deficiency in a multi-institutional endometrial cancer consortium

Patients with endometrial cancer are eligible for checkpoint inhibitor therapy based on their molecular signature, including mismatch repair deficiency (dMMR), microsatellite instability (MSI-H), and high tumor mutation burden (TMB H). The objective of this study was to compare the clinical characteristics and outcomes of patients who were found to be TMB H, MSI-H/dMMR, both, or neither.